Ascending, single dose study of the safety, tolerability, and pharmacokinetics of DVS [desvenlafaxine succinate] SR [sustained release] administered orally to healthy Japanese female subjects
Latest Information Update: 07 Jul 2010
Price :
$35 *
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Depression
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Wyeth
- 07 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
- 25 Nov 2006 New trial record.